4-methoxyphenylmethyleneaminoguanidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-methoxyphenylmethyleneaminoguanidine
• 英文别名: N-(4-Methoxybenzylideneamino)guanidine；2-[(4-methoxyphenyl)methylideneamino]guanidine
• 化学式: C₉H₁₂N₄O
• mdl: MFCD00276317
• 分子量: 192.22
• InChiKey: KBAGVDXUQHVTTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  86
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-methoxyphenylmethyleneaminoguanidine 、 色酮-3-甲醛 以 乙醇 为溶剂， 以71%的产率得到
  参考文献：
  名称：

  新型嘧啶-色基杂化衍生物作为潜在抗增殖剂的有效合成和分子对接研究

  摘要：

  摘要 含有嘧啶核 5 H-色基[4,3- d ]嘧啶（4a-c，e-h，l-r，t）和嘧啶-5-基-（2-羟基苯基）甲酮（5a，c , d , f–k , m–o , r , s , u)由脒腙(2a–u)和 3-甲酰基色酮(3)反应合成. 使用 MTT 分析方法针对人肝肝细胞癌细胞系 (HepG2) 和人乳腺腺癌细胞系 (MDA-MB-231) 测试了这些化合物。此外，还进行了分子对接计算，以比较各种新型杂环化合物对癌症蛋白质的生物活性。在这些计算中，使用的蛋白质是来自乳腺癌相关蛋白 1JNX 的 BRCT 重复区域的晶体结构、VEGFR 激酶（肝癌）蛋白的晶体结构、3WZE，以及变构 Eya2 磷酸盐抑制剂（肺癌）的晶体结构蛋白质，5ZMA，分别。经过分子对接计算、吸收、分布、代谢，

  DOI：

  10.1080/00397911.2021.1922920
• 作为产物：
  描述：

  氨基胍硝酸盐 、 4-甲氧基苯甲醛 在 水 、 sodium hydroxide 作用下， 生成 4-methoxyphenylmethyleneaminoguanidine
  参考文献：
  名称：

  新型嘧啶-色基杂化衍生物作为潜在抗增殖剂的有效合成和分子对接研究

  摘要：

  摘要 含有嘧啶核 5 H-色基[4,3- d ]嘧啶（4a-c，e-h，l-r，t）和嘧啶-5-基-（2-羟基苯基）甲酮（5a，c , d , f–k , m–o , r , s , u)由脒腙(2a–u)和 3-甲酰基色酮(3)反应合成. 使用 MTT 分析方法针对人肝肝细胞癌细胞系 (HepG2) 和人乳腺腺癌细胞系 (MDA-MB-231) 测试了这些化合物。此外，还进行了分子对接计算，以比较各种新型杂环化合物对癌症蛋白质的生物活性。在这些计算中，使用的蛋白质是来自乳腺癌相关蛋白 1JNX 的 BRCT 重复区域的晶体结构、VEGFR 激酶（肝癌）蛋白的晶体结构、3WZE，以及变构 Eya2 磷酸盐抑制剂（肺癌）的晶体结构蛋白质，5ZMA，分别。经过分子对接计算、吸收、分布、代谢，

  DOI：

  10.1080/00397911.2021.1922920

文献信息

• Synthesis, Antileishmanial Activity and in silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes
  作者：Thiago M. de Aquino、Paulo H. B. França、Érica E. E. S. Rodrigues、Igor. J.S. Nascimento、Paulo F. S. Santos-Júnior、Pedro G. V. Aquino、Mariana S. Santos、Aline C. Queiroz、Morgana V. Araújo、Magna S. Alexandre-Moreira、Raiza R. L. Rodrigues、Klinger A. F. Rodrigues、Johnnatan D. Freitas、Jacques Bricard、Mario R. Meneghetti、Jean-Jacques Bourguignon、Martine Schmitt、Edeildo F. da Silva-Júnior、João X. de Araújo-Júnior

  DOI：10.2174/1573406417666210216154428

  日期：2022.2

  Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most severe, fatal in 95% of cases. The undesired side-effects from first-line chemotherapy and the reported drug resistance search for effective drugs that can replace or supplement those currently used an urgent need. Aminoguanidine hydrazones (AGH's) have been explored for exhibiting a diverse spectrum of biological activities, in particular the antileishmanial activity of MGBG. The bioisosteres thiosemicarbazones (TSC's) offer a similar biological activity diversity, including antiprotozoal effects against Leishmania species and Trypanosoma cruzi.

  Considering the impact of leishmaniasis worldwide, this work aimed to design, synthesize, and perform a screening upon L. chagasi amastigotes and for the cytotoxicity of the small "in-house" library of both AGH and TSC derivatives and their structurally-related compounds.

  A set of AGH's (3-7), TSC's (9, 10), and semicarbazones (11) were initially synthesized. Subsequently, different semi-constrained analogs were designed and also prepared, including thiazolidines (12), dihydrothiazines (13), imidazolines (15), pyrimidines (16, 18) azines (19, 20), and benzotriazepinones (23-25). All intermediates and target compounds were obtained with satisfactory yields and exhibited spectral data consistent with their structures. All final compounds were evaluated against L. chagasi amastigotes and J774.A1 cell line. Molecular docking was performed towards trypanothione reductase using GOLD® software.

  The AGH's 3i, 4a, and 5d, and the TSC's 9i, 9k, and 9o were selected as valuable hits. These compounds presented antileishmanial activity compared with pentamidine, showing IC50 values ranged from 0.6 to 7.27 μM, maximal effects up to 55.3%, and satisfactory SI values (ranged from 11 to 87). On the other hand, most of the resulting semi-constrained analogs were found cytotoxic or presented reduced antileishmanial activity. In general, TSC class is more promising than its isosteric AGH analogs, and the beneficial aromatic substituent effects are not similar in both series. In silico studies have suggested that these hits are capable of inhibiting the trypanothione reductase from the amastigote forms.

  The promising antileishmanial activity of three AGH’s and three TSC’s was characterized. These compounds presented antileishmanial activity compared with PTD, showing IC50 values ranged from 0.6 to 7.27 μM, and satisfactory SI values. Further pharmacological assays involving other Leishmania strains are under progress, which will help to choose the best hits for in vivo experiments.

  背景：利什曼病是全球性健康问题，在发展中国家高度流行。在该病的四种主要临床形式中，内脏利什曼病是最严重的，95%的病例会致命。由于一线化疗药物的不良副作用和报道的药物耐药性，迫切需要寻找可以替代或补充当前使用的有效药物。氨基胍脒肼酮（AGH）已被探索用于展示多样的生物活性，特别是MGBG的抗利什曼病活性。生物同功异构体硫脲半胱氨酮（TSC）提供类似的生物活性多样性，包括对利什曼病和克氏锥虫的抗原虫效应。 目的：考虑到利什曼病在全球范围内的影响，本研究旨在设计、合成并对L. chagasi阿马斯蒂果虫进行筛选，以及对小型“内部”AGH和TSC衍生物及其结构相关化合物的细胞毒性进行评估。 方法：首先合成了一组AGH（3-7）、TSC（9, 10）和半胱氨酮（11）。随后，设计并制备了不同的半约束类似物，包括噻唑烷（12）、二氢噻嗪（13）、咪唑烷（15）、嘧啶（16, 18）、吲哚烷（19, 20）和苯并三唑环酮（23-25）。所有中间体和目标化合物均以满意的收率获得，并展示了与其结构一致的光谱数据。所有最终化合物均对L. chagasi阿马斯蒂果虫和J774.A1细胞系进行了评估。使用GOLD®软件对其进行了针对巯基还原酶的分子对接。 结果：AGH的3i、4a和5d以及TSC的9i、9k和9o被选为有价值的命中物。这些化合物与五环胺相比具有抗利什曼病活性，IC50值范围从0.6到7.27μM，最大效果高达55.3％，满意的SI值（范围从11到87）。另一方面，大多数结果的半约束类似物被发现具有细胞毒性或具有降低的抗利什曼病活性。总体而言，TSC类比其同功异构AGH类更有前景，而有益的芳香族取代作用在两个系列中并不相似。计算机模拟研究表明这些命中物能够抑制阿马斯蒂果虫的巯基还原酶。 结论：三种AGH和三种TSC的有前景的抗利什曼病活性得到了表征。这些化合物与PTD相比具有抗利什曼病活性，IC50值范围从0.6到7.27μM，SI值满意。正在进行涉及其他利什曼病菌株的进一步药理学评估，这将有助于选择最佳的命中物进行体内实验。
• Synthesis of novel heterocyclic compounds containing pyrimidine nucleus using the Biginelli reaction: Antiproliferative activity and docking studies
  作者：Sevtap Çağlar Yavuz、Senem Akkoç、Burçin Türkmenoğlu、Emin Sarıpınar

  DOI：10.1002/jhet.3978

  日期：2020.6

  guanyl hydrazone derivatives (3a‐n) . These compounds were tested as in vitro against two types of cancerous cell lines, namely, a human colon cancerous cell line (DLD‐1) and a human breast cancerous cell line (MDA‐MB‐231). According to the obtained results, nearly all the compounds have cytotoxic activity in the tested cell lines. Especially, the compounds 4j , 4k , and 4n had a significant effect against

  在一个反应​​步骤中，由芳香醛（1），氰基乙酸乙酯（2）和一些some衍生物（3a-n​​）的三重反应合成了嘧啶衍生物（4a-p ）。这些化合物在体外针对两种类型的癌细胞系进行了测试，分别是人结肠癌细胞系（DLD-1）和人乳腺癌细胞系（MDA-MB-231）。根据获得的结果，几乎所有化合物在测试的细胞系中均具有细胞毒活性。尤其是化合物4j，4k和4n对DLD-1具有明显的影响。此外，化合物4g，4m，和4o相比，针对MDA-MB-231的其他合成化合物，IC 50值更低。我们希望这些化合物将来可以作为抗癌药得到改进。根据拓扑异构酶I和N-乙酰转移酶1蛋白进行分子对接，从理论上检查具有最佳活性的嘧啶化合物的结合模式和位点。
• Synthesis, Biological Activity Evaluation and Molecular Docking of Imidazole Derivatives Possessing Hydrazone Moiety
  作者：Hüseyin Kekeçmuhammed、Michael Tapera、Ekrem Aydoğdu、Emin Sarıpınar、Elanur Aydin Karatas、Eda Mehtap Uc、Mesut Akyuz、Burak Tüzün、İlhami Gulcin、Rıfat Emin Bora、İlhan Özer İlhan

  DOI：10.1002/cbdv.202200886

  日期：2023.6

  Synthesized compounds were evaluated for their in vitro anticancer (prostate cell lines; PC3) and CA inhibitory (hCA I and hCA II) activity. Among them, some compound displayed remarkable anticancer activity and CA inhibitory activity with Ki values in range of 17.53±7.19–150.50±68.87 nM against cytosolic hCA I isoform associated with epilepsy, and 28.82±14.26–153.27±55.80 nM against dominant cytosolic

  为了鉴定具有低细胞毒性的潜在活性抗癌剂和CA抑制剂，通过氮杂-迈克尔加成反应和分子内环化合成了一系列新的杂化化合物，其中包含咪唑环和腙部分作为其结构的一部分。使用各种光谱技术阐明了合成化合物的结构。评估了合成化合物的体外抗癌（前列腺细胞系；PC3）和 CA 抑制（hCA I 和 hCA II）活性。其中，一些化合物表现出显着的抗癌活性和CA抑制活性，对与癫痫相关的胞质hCA I亚型的K i值在17.53±7.19–150.50±68.87 nM范围内，对主要胞质hCA的K i 值在28.82±14.26–153.27±55.80 nM范围内。与青光眼相关的 II 亚型。此外，还计算了生物活性分子的理论参数以确定其药物相似性。用于计算的蛋白质是前列腺癌蛋白质（PDB ID：3RUK 和 6XXP）。进行 ADME/T 分析以检查所研究分子的药物特性。
• Convergent synthesis and cruzain inhibitory activity of novel 2-(N′-benzylidenehydrazino)-4-trifluoromethyl-pyrimidines
  作者：Nilo Zanatta、Simone S. Amaral、Josiane M. dos Santos、Débora L. de Mello、Liana da S. Fernandes、Helio G. Bonacorso、Marcos A.P. Martins、Adriano D. Andricopulo、Deise M. Borchhardt

  DOI：10.1016/j.bmc.2008.10.052

  日期：2008.12.15

  To search for new cruzain inhibitors, the synthesis of a series of novel 2-(N'-benzylidenehydrazino)-4-trifluoromethyl-pyrimidines in a convergent manner is presented. The cruzain inhibitory activity of some of these compounds was evaluated and a binding model was proposed. All derivatives tested were active and the most significant inhibitory effect (80% at 100 mu M) and IC(50) value (85 mu M) were obtained from the 2-(N'-4-chloro-benzylidenehydrazino)-4-trifluoromethyl-pyrimidine. Although further structural optimization to improve solubility is necessary, the molecular docking studies suggest that these inhibitors occupy the S2 pocket without irreversible enzyme inactivation, through hydrophobic interactions, thus, indicating a desirable mode of interaction for the design of novel inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.
• Synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular docking studies of new imidazolyl hydrazone derivatives
  作者：Michael Tapera、Hüseyin Kekeçmuhammed、Burak Tüzün、Emin Sarıpınar、Ümit M. Koçyiğit、Ebrar Yıldırım、Murat Doğan、Yunus Zorlu

  DOI：10.1016/j.molstruc.2022.133816

  日期：2022.12